UTHR EVP & General Counsel Paul A Mahon Sells $4.5M of Stock

Paul A. Mahon, executive vice president and general counsel of United Therapeutics Corporation (NasdaqGS: UTHR), sold 8,300 shares of the company on October 15, 2026. The transaction was executed at an average price of $544.30 per share, for a total value of $4.5 million. According to a Form 4 filed with the Securities and Exchange Commission, the sale was carried out under a pre-arranged Rule 10b5-1 trading plan.

Inside Paul A. Mahon's United Therapeutics Trade

The planned sale reduced Mahon's direct stake in the specialty drug maker by 15.52%. Following the transaction, he holds 45,172 shares of the company. On the day of the trade, United Therapeutics shares closed at $541.51.

Other Institutional Activity in United Therapeutics

Other large funds have also adjusted their holdings in the drug developer. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.48 billion. Renaissance Technologies, LLC trimmed its position by 78,271 shares, leaving it with 1,708,739 shares valued at $911.0 million. Meanwhile, Jupiter Topco LLC doubled its stake with a 100.0% increase, adding 415,564 shares to finish with 831,129 shares worth about $443.1 million.

United Therapeutics Corporation Stock Up 0.1%

United Therapeutics shares recently traded around $541.98, putting the stock up about 5.3% above its 50-day moving average of $514.66 and about 2.9% above its 200-day moving average of $526.82. The stock remains about 11.1% below its 52-week high of $609.35 and sits well above its 52-week low of $409.07. The timing puts this insider trade just weeks before the company's next earnings report, which is scheduled for October 28, 2026.

Recent Earnings

United Therapeutics reported trailing twelve months revenue of $3.15 billion and earnings of $27.92 per share. The company generated a net margin of 41.6% and a return on equity of 19.3%, alongside a year-over-year revenue decline of 1.9%.

Insider Buying and Selling at United Therapeutics Corporation

Mahon's transaction follows a string of planned sales by Chief Executive Officer Martine Rothblatt. Rothblatt sold 9,500 shares on October 9 for $5.2 million, another 9,500 shares on October 12 for $5.2 million, a third block of 9,500 shares on October 13 for $5.2 million, and a fourth block of 9,500 shares on October 14 for $5.1 million.

Analysts Set New Price Targets

Wall Street firms have kept a mixed outlook on the stock through recent months. RBC Capital maintained an Outperform rating while raising its price target to $708.00 on October 8, following an earlier target of $677.00 set on August 6. Morgan Stanley maintained an Equal-Weight rating and raised its target to $566.00 on October 7. Earlier in the fall, BTIG upgraded the stock to a Buy with a $728.00 target on October 1, Goldman Sachs initiated a Sell rating with a $321.00 target on September 24, and the broader analyst consensus sits at a buy recommendation with a mean price target of $656.93 across 14 opinions.

About United Therapeutics

Headquartered in Silver Spring, Maryland, United Therapeutics Corporation focuses on developing and commercializing medicines to treat rare and life-threatening conditions, particularly in specialty therapeutics. Founded by Dr. Martine Rothblatt, the company employs about 1,400 people and maintains a strong financial profile with high profit margins.

Bottom Line

Insiders continue executing planned sales ahead of the company's upcoming earnings release on October 28, 2026. Investors will be watching the next round of financial results and future Form 4 filings to see how executives manage their remaining equity positions.